SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Östlund Ollie) "

Sökning: WFRF:(Östlund Ollie)

  • Resultat 41-44 av 44
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Völz, Sebastian, et al. (författare)
  • Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management : A prespecified subgroup analysis from VALIDATE-SWEDEHEART
  • 2019
  • Ingår i: European Heart Journal. - : Sage Publications. - 2048-8726 .- 2048-8734. ; 8:6, s. 510-519
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims: In the Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated according to Recommended Therapies Registry Trial (VALIDATE-SWEDEHEART), bivalirudin was not superior to unfractionated heparin in patients with acute coronary syndrome undergoing invasive management. We assessed whether the access site had an impact on the primary endpoint of death, myocardial infarction or major bleeding at 180 days and whether it interacted with bivalirudin/unfractionated heparin.Methods and results: A total of 6006 patients with acute coronary syndrome planned for percutaneous coronary intervention were randomised to either bivalirudin or unfractionated heparin. Arterial access was left to the operator discretion. Overall, 90.5% of patients underwent transradial access and 9.5% transfemoral access. Baseline risk was higher in transfemoral access. The unadjusted hazard ratio for the primary outcome was lower with transradial access (hazard ratio 0.53, 95% confidence interval 0.43-0.67, p<0.001) and remained lower after multivariable adjustment (hazard ratio 0.56, 95% confidence interval 0.52-0.84, p<0.001). Transradial access was associated with lower risk of death (hazard ratio 0.41, 95% confidence interval 0.28-0.60, p<0.001) and major bleeding (hazard ratio 0.57, 95% confidence interval 0.44-0.75, p<0.001). There was no interaction between treatment with bivalirudin and access site for the primary endpoint (p=0.976) or major bleeding (p=0.801).Conclusions: Transradial access was associated with lower risk of death, myocardial infarction or major bleeding at 180 days. Bivalirudin was not associated with less bleeding, irrespective of access site.
  •  
42.
  •  
43.
  • Wallentin, Lars, et al. (författare)
  • Lipoprotein-Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
  • 2016
  • Ingår i: Journal of the American Heart Association. - 2047-9980. ; 5:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Background - We evaluated lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp-PLA(2) inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial.Methods and Results - Plasma Lp-PLA(2) activity was determined at baseline (n=14 500); at 1 month (n=13 709); serially (n=100) at 3, 6, and 18 months; and at the end of treatment. Adjusted Cox regression models evaluated associations between Lp-PLA(2) activity levels and outcomes. At baseline, the median Lp-PLA(2) level was 172.4 mu mol/min per liter (interquartile range 143.1-204.2 mu mol/min per liter). Comparing the highest and lowest Lp-PLA(2) quartile groups, the hazard ratios were 1.50 (95% CI 1.23-1.82) for the primary composite end point (cardiovascular death, myocardial infarction, or stroke), 1.95 (95% CI 1.29-2.93) for hospitalization for heart failure, 1.42 (1.07-1.89) for cardiovascular death, and 1.37 (1.03-1.81) for myocardial infarction after adjustment for baseline characteristics, standard laboratory variables, and other prognostic biomarkers. Treatment with darapladib led to a approximate to 65% persistent reduction in median Lp-PLA(2) activity. There were no associations between on-treatment Lp-PLA(2) activity or changes of Lp-PLA(2) activity and outcomes, and there were no significant interactions between baseline and on-treatment Lp-PLA(2) activity or changes in Lp-PLA(2) activity levels and the effects of darapladib on outcomes.Conclusions - Although high Lp-PLA(2) activity was associated with increased risk of cardiovascular events, pharmacological lowering of Lp-PLA(2) activity by approximate to 65% did not significantly reduce cardiovascular events in patients with stable coronary heart disease, regardless of the baseline level or the magnitude of change of Lp-PLA(2) activity.
  •  
44.
  • Yndigegn, Troels, et al. (författare)
  • Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)
  • 2022
  • Ingår i: European Heart Journal - Cardiovascular Pharmacotherapy. - : Oxford University Press. - 2055-6837 .- 2055-6845. ; 9:2, s. 192-197
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Most trials showing benefit of beta-blocker treatment after myocardial infarction (MI) included patients with large MIs and are from an era before modern biomarker-based MI diagnosis and reperfusion treatment. The aim of the Randomized Evaluation of Decreased Usage of betabloCkErs after Acute Myocardial Infarction (REDUCE-AMI) trial is to determine whether long-term oral beta-blockade in patients with an acute MI and preserved left ventricular ejection fraction (EF) reduces the composite endpoint of death of any cause or recurrent MI.METHODS: It is a registry-based, randomized, parallel, open-label, multicenter trial performed at 38 centers in Sweden, one center in Estonia and six centers in New Zealand. About 5000 patients with an acute MI who have undergone coronary angiography and with EF ≥ 50% will be randomized to long-term treatment with beta-blockade or not. The primary endpoint is the composite endpoint of death of any cause or new non-fatal MI. There are several secondary endpoints, including all-cause death, cardiovascular death, new MI, readmission because of heart failure and atrial fibrillation, symptoms, functional status, health related quality of life after 6-10 weeks and after 1 year of treatment. Safety endpoints are bradycardia, AV-block II-III, hypotension, syncope or need for pacemaker, asthma or chronic obstructive pulmonary disease and stroke.CONCLUSION: The results from REDUCE-AMI will add important evidence regarding the effect of beta-blockers in patients with MI and preserved EF and may change guidelines and clinical practice.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-44 av 44
Typ av publikation
tidskriftsartikel (41)
annan publikation (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (38)
övrigt vetenskapligt/konstnärligt (6)
Författare/redaktör
Östlund, Ollie (44)
Erlinge, David (18)
Omerovic, Elmir (11)
Hofmann, Robin (11)
James, Stefan, 1964- (10)
Kellerth, Thomas (9)
visa fler...
Herlitz, Johan, 1949 (8)
Fröbert, Ole, 1964- (8)
Hagström, Emil (8)
Lindahl, Bertil, 195 ... (8)
Jernberg, Tomas (8)
Koenig, Wolfgang (8)
Held, Claes, 1956- (7)
Wallentin, Lars (7)
Held, Claes (7)
Linder, Rikard (7)
Koul, Sasha (6)
Jensen, Jens (6)
James, Stefan K (6)
James, Stefan K., 19 ... (6)
Rubertsson, Sten (6)
Budaj, Andrzej (6)
Danielewicz, Mikael (6)
Andersson, Jonas (5)
Lauermann, Jörg (5)
Wallentin, Lars, 194 ... (5)
Steg, Philippe Gabri ... (5)
White, Harvey D. (5)
Lindgren, Erik (5)
Sparv, David (5)
Angerås, Oskar (5)
Stewart, Ralph A H (5)
Ulvenstam, Anders (5)
Hamid, Mehmet (5)
Henareh, Loghman (5)
Herlitz, Johan (4)
Ravn-Fischer, Annica ... (4)
Omerovic, Elmir, 196 ... (4)
Götberg, Matthias (4)
Pernow, John (4)
Alfredsson, Joakim (4)
Yndigegn, Troels (4)
Cannon, Christopher ... (4)
Sarno, Giovanna (4)
Ioanes, Dan (4)
Witt, Nils (4)
Wagner, Henrik (4)
Karlsten, Rolf (4)
Soffer, Joseph (4)
Östlund, Olof Petter (4)
visa färre...
Lärosäte
Uppsala universitet (41)
Karolinska Institutet (28)
Lunds universitet (20)
Linköpings universitet (13)
Högskolan i Borås (11)
Umeå universitet (10)
visa fler...
Göteborgs universitet (9)
Örebro universitet (9)
Kungliga Tekniska Högskolan (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (44)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (40)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy